MPM BioVentures 2014, L.P. (EVNIN LUKE, GADICKE ANSBERT) sold $616K of TRDA (indirect holdings)
MPM BioVentures 2014, L.P. sold 86,914 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.08 ($6.99–$7.20, $0.62M total) across 3 trades over 2026-08-27 to 2026-08-31. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).
How this was made
The 30-second read
Why it matters
Provides primary source data on insider activity, useful for short-term sentiment assessment.
Market read
Insider sell of ~0.6M USD may cause modest price movement; relevant for short-term traders.
What to watch
Potential upcoming clinical data or financing events not disclosed.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Insider MPM BioVentures sold 86,914 shares of Entrada Therapeutics at $7.08 avg, total $615,777.
Potential slight downward pressure on TRDA price in the short term.
The transaction size (~$0.6M) is small relative to market cap, but insider sell signals possible lack of confidence.
Market effects
Minimal impact on biotech sector; typical insider sell activity.
No significant regional effect.
Limited to investors tracking Entrada Therapeutics.
Counterpoint
The sale could be a routine liquidity move, not a bearish signal.
Key entities
- CompanyEntrada Therapeutics, Inc.
Biotech firm listed on NASDAQ under ticker TRDA.
- InvestorMPM BioVentures 2014, L.P.
Insider reporting a 10% ownership stake.
